VNY
Thuốc thú y Trung ương I ·UPCOM ·2026Q1
▲▲ Improving positively
TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity
What Is Changing
On a TTM 2026Q1 basis, VNY has not accelerated revenue sharply, but profitability is improving visibly — profit is at an all-time high. Profit growth is driven mainly by better operations rather than scale expansion — a foundation that tends to be more durable.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.5 | 32.0 | 30.7 | 26.1 | 22.9 | 33.4 | 23.0 | 29.5 | 24.3 | 26.6 | 22.4 | 21.4 |
| Growth | -23% | +4% | +18% | +14% | -32% | +45% | -22% | +22% | -9% | +18% | +5% | — |
| Net Income | 1.1 | 4.3 | 1.1 | 2.5 | 0.6 | 1.7 | 0.6 | 0.9 | 0.2 | 1.8 | 0.5 | 0.5 |
| Net Margin | 4.35% | 13.34% | 3.55% | 9.58% | 2.59% | 5.13% | 2.64% | 2.95% | 0.94% | 6.68% | 2.38% | 2.28% |
Drivers of VNY's profit
Net profit attributable to parent increased vs last year, mainly helped by lower selling expenses. Supporting and offsetting drivers:
Net profit attributable to parent increased vs prior quarter, mainly helped by lower selling expenses. Supporting and offsetting drivers:
Financial Highlights
Detailed analysis of each financial dimension
ROE = Profit Margin × Asset Turnover × Equity Multiplier
ROE rose from 3.8% to 8.4% — mainly driven by net margin, despite leverage moving in the opposite direction.
Is the profit sustainable?
Margins are improving and earnings quality is solid — a durable foundation for ROE.
What is driving the margin?
Net margin expanded to 7.88%, rising 4.4pp. Core operating signals are improving as SG&A / Revenue fell 4.0pp are enough to offset pressure from Gross margin fell 0.1pp (with additional support from Other profit / Revenue rose 1.3pp and Net financial result / Revenue rose 0.3pp).
Margin improves from both core operations and non-core items — the core foundation is positive, but the sustainability of non-core contributions needs monitoring.
Profitability trend
TTM YoY · 2025Q1 -> 2026Q1
Is capital being used efficiently?
Return on capital rose, but cash cycle lengthened by 15.8 days — working capital needs watching.
Is capital being deployed efficiently?
ROIC expanded to 7.99%, rising 4.3pp. That translates to 7.99 in after-tax operating profit for every 100 units of operating capital. The main driver is NOPAT margin rose 3.3pp, with capital turnover broadly stable; with invested capital holding roughly steady.
NOPAT margin expansion has lifted ROIC above the deposit-rate threshold but below typical cost of equity — more same-direction periods are needed to confirm a structural shift.
CAPITAL EFFICIENCY TREND
TTM YoY · 2025Q1 -> 2026Q1
Balance Sheet
ROIC is improving — the asset structure below shows how capital is being allocated. Balance sheet is exceptionally sound — liabilities at 0.49x equity, with a net cash position equivalent to 0.19x equity.
Inventory ended the period at 18.8bn, roughly 11.5% of total assets.
Over the last 12 months, working capital absorbed 1.5bn of cash, mainly because of higher receivables and lower payables. Part of that drag was offset by lower inventories.
Working Capital Drivers
TTM YoY · 2025Q1 -> 2026Q1
Working Capital Efficiency
The inventory build-up noted above is reflected in a longer cash cycle. Cash conversion cycle lengthened by 15.8 days versus the same period last year. The main moves came from DIO fell 7.5 days, DSO rose 15.7 days, and DPO fell 7.7 days.
Working capital cycle lengthened mainly due to slower receivables collection — receivables quality needs monitoring.
Watchpoints
CCC is up by +15.8 days, indicating weaker working-capital turnover versus the prior year.
DSO increased by +15.7 days, pointing to slower receivables turnover.
Working Capital Efficiency
TTM YoY · 2025Q1 -> 2026Q1
Is financial risk significant?
Financial risk is low — the company has net cash and CFO reached 11.3bn.
Leverage & Liquidity
Leverage looks fairly comfortable, with net debt / equity at -0.19x and interest coverage at 14.75x.
At present, cash equals 281.4% of debt and total debt stands at 11.8bn.
Leverage and liquidity trend
TTM YoY · 2025Q1 -> 2026Q1
Cash Flow
With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 11.3bn in 2025, against investing cash flow of -1.2bn.
Post-investment cash flow was positive +10.1bn. Financing cash flow was positive 0.0bn.
CFO / net income was 1.09x.
After spending +2.7bn on fixed-asset investment, the business generated trailing free cash flow of +7.0bn.
Cash Conversion
TTM Cash Conversion · 2025Q1 -> 2026Q1
Investment Takeaway
The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is operating efficiency, with net margin improving 4.4 pp. The next item to monitor is the earnings mix, when non-core contribution is 20.5%.
Improvement: operating efficiency is getting better, with trailing-12M net margin at 7.88% after expanding 4.4pp versus the same period last year.
Watchpoint: cash flow is currently keeping pace with accounting earnings, with CFO / net income at 1.09x. Even so, net financial result still accounts for 20.5% of PBT, so the earnings mix still needs monitoring.
Statement Data
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Net Revenue
|
111.7 | 109.1 | 94.3 | 138.6 |
|
Cost of Goods Sold
|
83.2 | 81.9 | 70.9 | 111.4 |
|
Gross Profit
|
28.5 | 27.2 | 23.4 | 27.2 |
|
Financial Expenses
|
0.7 | 0.9 | 0.7 | 2.0 |
|
Selling Expenses
|
10.2 | 12.8 | 11.8 | 12.8 |
|
General and Administrative Expenses
|
9.8 | 9.9 | 9.0 | 9.3 |
|
Operating Profit
|
8.5 | 4.3 | 2.6 | 3.8 |
|
Profit Before Tax
|
10.8 | 5.1 | 4.3 | 6.2 |
|
Net Income
|
8.5 | 3.8 | 3.4 | 5.6 |
|
Profit Attributable to Parent
|
8.5 | 3.8 | 3.4 | 5.6 |
|
Earnings per Share
|
508.00 | 220.00 | 211.00 | 393.00 |
Explore Other Stocks In The Same Sector
DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP
Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.